T5O0 — bioXXmed AG Share Price
Last trade - 00:00- €1.07m
- €0.98m
- €0.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.88 | ||
| Price to Tang. Book | 9.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 213.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -349.22% | ||
| Return on Equity | -197.97% | ||
| Operating Margin | -17916.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 0.04 | 0.04 | 0.04 | 0.01 | 0.02 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
bioXXmed AG is a Germany-based holding company that invests in biotechnological or medical technology companies with equity or borrowed capital. The Company holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. bioXXmed AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections.
Directors
- Heiner Hoppmann CSU
- Mark-Andre Freyberg CMG
- Matthias Hoffmann VSU
- Dirk Kaiser MGB
- Peter Friedl SUB
- Manfred May SUB
- Bernhard Seehaus SUB
- Ruediger Weseloh SUB
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- August 23rd, 2006
- Public Since
- May 18th, 2007
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- XETRA
- Shares in Issue
- 1,359,328
- Address
- Riedstrasse 2, DARMSTADT, 64295
- Web
- https://bioxxmed.ag/
- Phone
- +49 61519515812
- Contact
- Bruno Rosen
- Auditors
- Not Available
Upcoming Events for T5O0
Similar to T5O0
FAQ
As of Today at 19:36 UTC, shares in bioXXmed AG are trading at €0.78. This share price information is delayed by 15 minutes.
Shares in bioXXmed AG last closed at €0.78 and the price had moved by -79.04% over the past 365 days. In terms of relative price strength the bioXXmed AG share price has underperformed the FTSE Global All Cap Index by -80.42% over the past year.
The overall consensus recommendation for bioXXmed AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morebioXXmed AG does not currently pay a dividend.
bioXXmed AG does not currently pay a dividend.
bioXXmed AG does not currently pay a dividend.
To buy shares in bioXXmed AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.78, shares in bioXXmed AG had a market capitalisation of €1.07m.
Here are the trading details for bioXXmed AG:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: T5O0
Based on an overall assessment of its quality, value and momentum bioXXmed AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in bioXXmed AG is €25.40. That is 3139.8% above the last closing price of €0.78.
Analysts covering bioXXmed AG currently have a consensus Earnings Per Share (EPS) forecast of -€1.31 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like bioXXmed AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -40.56%.
As of the last closing price of €0.78, shares in bioXXmed AG were trading -65.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The bioXXmed AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
bioXXmed AG's management team is headed by:
- Heiner Hoppmann - CSU
- Mark-Andre Freyberg - CMG
- Matthias Hoffmann - VSU
- Dirk Kaiser - MGB
- Peter Friedl - SUB
- Manfred May - SUB
- Bernhard Seehaus - SUB
- Ruediger Weseloh - SUB